Related Experiment Video
Updated: Jun 22, 2026
07:29
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Variation in paraoxonase-1 activity and atherosclerosis
Handrean Soran1, Nahla N Younis, Valentine Charlton-Menys
1University Department of Medicine, Central Manchester and Manchester Children's University Hospitals Foundation Trust, Manchester, UK.
Current Opinion in Lipidology
|June 25, 2009
Summary
Paraoxonase-1 (PON1) is an HDL-associated enzyme that protects against cardiovascular disease by preventing LDL oxidation. Higher PON1 activity is linked to reduced cardiovascular events, suggesting it as a therapeutic target.
Area of Science:
- Biochemistry
- Cardiovascular Science
- Molecular Biology
Background:
- Paraoxonase-1 (PON1) is an HDL-associated protein synthesized in the liver.
- PON1 contributes to the antioxidant and anti-inflammatory properties of HDL.
- PON1 inhibits LDL oxidative modification, a key process in atherosclerosis.
Purpose of the Study:
- To review the relationship between PON1 activity and atherosclerotic diseases.
- To discuss factors modulating PON1 activity, including genetics, age, lifestyle, and medical conditions.
- To summarize evidence on pharmacological agents affecting PON1 activity.
Main Methods:
- Literature review of animal and human studies.
- Analysis of prospective studies on PON1 activity and cardiovascular events.
- Synthesis of data on factors influencing PON1 levels and activity.
Main Results:
- Low PON1 activity is increasingly linked to higher cardiovascular disease risk.
- Prospective studies show significantly fewer cardiovascular events in individuals with high PON1 activity.
- PON1 activity is associated with systemic lipid peroxidation and cardiovascular risk.
Conclusions:
- PON1 is an antiatherogenic enzyme protecting LDL from oxidation.
- Enhancing PON1 activity is a potential therapeutic strategy for reducing cardiovascular risk.
- Targeting PON1 may offer a novel approach for managing atherosclerotic diseases.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:24Peroxisomes
Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:22Cholinesterases: Distribution and Function
Cholinesterases are a group of serine hydrolase enzymes that play a crucial role in the breakdown of choline esters. The two primary types of cholinesterases are acetylcholinesterases (AChEs) and butyrylcholinesterase (BuChEs), which differ in their distribution, function, and substrate specificity. AChEs, also known as true cholinesterases, specifically hydrolyze acetylcholine, while BuChEs, often referred to as pseudocholinesterases, can hydrolyze various choline esters, including...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...